You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePirfenidone
Accession NumberDB04951
TypeSmall Molecule
GroupsInvestigational
DescriptionPirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EsbrietCapsule267 mg/1OralGenentech, Inc.2014-10-16Not applicableUs
EsbrietCapsule267 mgOralRoche Registration Limited2011-02-28Not applicableEu
EsbrietCapsule267 mg/1OralInter Mune, Inc.2014-10-16Not applicableUs
EsbrietCapsule267 mgOralRoche Registration Limited2011-02-28Not applicableEu
EsbrietCapsule267 mgOralHoffmann La Roche Limited2013-01-08Not applicableCanada
EsbrietCapsule267 mgOralRoche Registration Limited2011-02-28Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIID7NLD2JX7U
CAS number53179-13-8
WeightAverage: 185.2218
Monoisotopic: 185.084063979
Chemical FormulaC12H11NO
InChI KeyISWRGOKTTBVCFA-UHFFFAOYSA-N
InChI
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
IUPAC Name
5-methyl-1-phenyl-1,2-dihydropyridin-2-one
SMILES
CC1=CN(C(=O)C=C1)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of idiopathic pulmonary fibrosis (IPF).
Structured Indications Not Available
PharmacodynamicsPirfenidone is a novel agent with anti-inflammatory, antioxidant, and antifibrotic properties. It may improve lung function and reduce the number of acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF).
Mechanism of actionPirfenidone is an orally active, small molecule that shows a wide range of biologic activity. In vitro evidence has shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation. Pirfenidone leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin. In addition, pirfenidone reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis.
TargetKindPharmacological actionActionsOrganismUniProt ID
FurinProteinunknownNot AvailableHumanP09958 details
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life2-2.5 hours
ClearanceNot Available
ToxicityGenerally well tolerated with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 5-androstenedione.Experimental, Illicit
AbataceptThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Abatacept.Approved
AbciximabPirfenidone may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Pirfenidone can be increased when it is combined with Abiraterone.Approved
AcebutololPirfenidone may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Aceclofenac.Approved
AcenocoumarolPirfenidone may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Acetovanillone.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pirfenidone.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pirfenidone.Approved, Vet Approved
AclarubicinPirfenidone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pirfenidone.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alendronic acid.Approved
AliskirenPirfenidone may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololPirfenidone may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Pirfenidone.Approved, Investigational
ALT-110The risk or severity of adverse effects can be increased when Pirfenidone is combined with ALT-110.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Amcinonide.Approved
AmikacinPirfenidone may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmiloridePirfenidone may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinPirfenidone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Anakinra.Approved
AncrodPirfenidone may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Anisodamine.Investigational
annamycinPirfenidone may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pirfenidone.Approved
Antithrombin III humanPirfenidone may increase the anticoagulant activities of Antithrombin III human.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Pirfenidone.Investigational
Aop200704Pirfenidone may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanPirfenidone may increase the anticoagulant activities of Apixaban.Approved
ApramycinPirfenidone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Apremilast.Approved, Investigational
ArbekacinPirfenidone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinPirfenidone may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanPirfenidone may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPirfenidone may decrease the antihypertensive activities of Arotinolol.Approved
AtenololPirfenidone may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pirfenidone.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pirfenidone.Approved
AzithromycinThe serum concentration of Pirfenidone can be increased when it is combined with Azithromycin.Approved
BalsalazidePirfenidone may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Pirfenidone.Investigational
BecaplerminPirfenidone may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPirfenidone may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pirfenidone.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pirfenidone.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pirfenidone.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pirfenidone.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Betamethasone.Approved, Vet Approved
BetaxololPirfenidone may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Betulinic Acid.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Pirfenidone.Approved, Investigational
BevantololPirfenidone may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
BisoprololPirfenidone may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPirfenidone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololPirfenidone may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe serum concentration of Pirfenidone can be increased when it is combined with Bortezomib.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pirfenidone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Bucillamine.Investigational
BucindololPirfenidone may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Budesonide.Approved
BufuralolPirfenidone may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanidePirfenidone may decrease the diuretic activities of Bumetanide.Approved
BupranololPirfenidone may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirfenidone.Approved
CaffeineThe serum concentration of Pirfenidone can be increased when it is combined with Caffeine.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Canakinumab.Approved, Investigational
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Pirfenidone.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pirfenidone.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pirfenidone.Approved
CarbamazepineThe serum concentration of Pirfenidone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Pirfenidone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pirfenidone.Approved, Vet Approved, Withdrawn
CarteololPirfenidone may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPirfenidone may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pirfenidone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Pirfenidone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Celecoxib.Approved, Investigational
CeliprololPirfenidone may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
Certolizumab pegolPirfenidone may increase the immunosuppressive activities of Certolizumab pegol.Approved
CertoparinPirfenidone may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pirfenidone.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pirfenidone.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pirfenidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pirfenidone.Approved
CinoxacinPirfenidone may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinThe serum concentration of Pirfenidone can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CiprofloxacinPirfenidone may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Pirfenidone can be increased when it is combined with Citalopram.Approved
Citric AcidPirfenidone may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Pirfenidone.Vet Approved
ClotrimazoleThe serum concentration of Pirfenidone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Curcumin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pirfenidone.Approved, Investigational
CyclosporinePirfenidone may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with D-Limonene.Investigational
Dabigatran etexilatePirfenidone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinPirfenidone may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPirfenidone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinPirfenidone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with dehydroepiandrosterone sulfate.Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pirfenidone.Approved
DesirudinPirfenidone may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pirfenidone.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Pirfenidone.Approved
DextranPirfenidone may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Pirfenidone may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Pirfenidone may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Pirfenidone may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pirfenidone.Approved, Vet Approved
DicoumarolPirfenidone may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pirfenidone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pirfenidone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pirfenidone.Approved
DihydrostreptomycinPirfenidone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Pirfenidone.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Pirfenidone.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Pirfenidone.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirfenidone.Approved, Investigational
DoxorubicinPirfenidone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenonePirfenidone may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Pirfenidone is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ebselen.Investigational
Edetic AcidPirfenidone may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPirfenidone may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pirfenidone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pirfenidone.Approved
EnoxacinPirfenidone may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinPirfenidone may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Epirizole.Approved
EpirubicinPirfenidone may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenonePirfenidone may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pirfenidone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pirfenidone.Approved
EquileninThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Equilin.Approved
EsmololPirfenidone may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Estrone sulfate.Approved
Etacrynic acidPirfenidone may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Pirfenidone.Approved, Investigational
Ethyl biscoumacetatePirfenidone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Pirfenidone is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pirfenidone.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Pirfenidone.Vet Approved
FingolimodPirfenidone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinPirfenidone may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pirfenidone.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fludrocortisone.Approved
FluindionePirfenidone may increase the anticoagulant activities of Fluindione.Investigational
FlumequinePirfenidone may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Pirfenidone.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pirfenidone.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluticasone Propionate.Approved
FluvoxamineThe serum concentration of Pirfenidone can be increased when it is combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pirfenidone.Approved, Nutraceutical, Vet Approved
FondaparinuxPirfenidone may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPirfenidone may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Pirfenidone.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pirfenidone.Approved
FramycetinPirfenidone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemidePirfenidone may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Pirfenidone is combined with G17DT.Investigational
GabexatePirfenidone may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinPirfenidone may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPirfenidone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Pirfenidone.Approved, Withdrawn
GemifloxacinPirfenidone may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinPirfenidone may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPirfenidone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APirfenidone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The risk or severity of adverse effects can be increased when Pirfenidone is combined with GI-5005.Investigational
GrepafloxacinPirfenidone may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Pirfenidone is combined with HE3286.Investigational
HeparinPirfenidone may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Higenamine.Investigational
HirulogPirfenidone may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Pirfenidone is combined with HMPL-004.Investigational
HydralazinePirfenidone may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pirfenidone.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pirfenidone.Approved
Hygromycin BPirfenidone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pirfenidone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Icatibant.Approved
IdarubicinPirfenidone may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxPirfenidone may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pirfenidone.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pirfenidone.Approved
IndenololPirfenidone may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pirfenidone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Indoprofen.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Pirfenidone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pirfenidone is combined with INGN 225.Investigational
INNO-206Pirfenidone may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pirfenidone.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Istaroxime.Investigational
KanamycinPirfenidone may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pirfenidone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pirfenidone.Approved
LabetalolPirfenidone may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Leflunomide.Approved, Investigational
LepirudinPirfenidone may increase the anticoagulant activities of Lepirudin.Approved
LevobunololPirfenidone may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPirfenidone may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LidocaineThe serum concentration of Pirfenidone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Pirfenidone.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pirfenidone.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Pirfenidone.Approved
LomefloxacinPirfenidone may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Pirfenidone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Pirfenidone.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Pirfenidone.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pirfenidone.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pirfenidone.Approved
ME-609The risk or severity of adverse effects can be increased when Pirfenidone is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pirfenidone.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pirfenidone.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pirfenidone.Approved, Vet Approved
MesalazinePirfenidone may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pirfenidone.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Pirfenidone.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pirfenidone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Methylprednisolone.Approved, Vet Approved
MetipranololPirfenidone may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pirfenidone.Approved
MetoprololPirfenidone may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamidePirfenidone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe serum concentration of Pirfenidone can be increased when it is combined with Mexiletine.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pirfenidone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pirfenidone.Approved
MometasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pirfenidone.Approved
MoxifloxacinPirfenidone may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pirfenidone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pirfenidone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Nabumetone.Approved
NadololPirfenidone may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPirfenidone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatPirfenidone may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Pirfenidone.Approved
Nalidixic AcidPirfenidone may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pirfenidone.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Pirfenidone is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Pirfenidone is combined with NCX 4016.Investigational
NeaminePirfenidone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinPirfenidone may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPirfenidone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Nepafenac.Approved
NetilmicinPirfenidone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NevirapineThe serum concentration of Pirfenidone can be increased when it is combined with Nevirapine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pirfenidone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pirfenidone.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Pirfenidone.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Nitroaspirin.Investigational
NorfloxacinPirfenidone may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinPirfenidone may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pirfenidone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pirfenidone.Approved
OlsalazinePirfenidone may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Pirfenidone.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Orgotein.Vet Approved
OtamixabanPirfenidone may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Pirfenidone.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pirfenidone.Approved
OxprenololPirfenidone may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pirfenidone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirfenidone.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Parecoxib.Approved
ParomomycinPirfenidone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinPirfenidone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPirfenidone may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPirfenidone may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfatePirfenidone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pirfenidone.Approved
PhenindionePirfenidone may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Pirfenidone can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonPirfenidone may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pirfenidone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirfenidone.Approved, Investigational
PindololPirfenidone may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinPirfenidone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanidePirfenidone may decrease the diuretic activities of Piretanide.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pirfenidone.Approved, Investigational
PlicamycinPirfenidone may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pirfenidone.Approved
PractololPirfenidone may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Pirfenidone.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pregnenolone.Experimental
PrimidoneThe serum concentration of Pirfenidone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Pirfenidone can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Propacetamol.Approved
PropranololPirfenidone may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Pirfenidone.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Pirfenidone.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Pirfenidone.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Pirfenidone.Vet Approved
Protein CPirfenidone may increase the anticoagulant activities of Protein C.Approved
Protein S humanPirfenidone may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePirfenidone may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPirfenidone may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Pirfenidone is combined with PTC299.Investigational
PuromycinPirfenidone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pirfenidone.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pirfenidone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Pirfenidone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pirfenidone.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pirfenidone.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pirfenidone.Experimental, Investigational
ReviparinPirfenidone may increase the anticoagulant activities of Reviparin.Approved
RibostamycinPirfenidone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe serum concentration of Pirfenidone can be decreased when it is combined with Rifampicin.Approved
RilonaceptThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rilonacept.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Risedronate.Approved, Investigational
RivaroxabanPirfenidone may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rofecoxib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Pirfenidone.Approved
RopiniroleThe serum concentration of Pirfenidone can be increased when it is combined with Ropinirole.Approved, Investigational
RosoxacinPirfenidone may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Pirfenidone.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pirfenidone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pirfenidone.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pirfenidone.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Pirfenidone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Seratrodast.Approved, Investigational
SimeprevirThe serum concentration of Pirfenidone can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pirfenidone.Approved
SisomicinPirfenidone may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolPirfenidone may decrease the antihypertensive activities of Sotalol.Approved
SP1049CPirfenidone may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinPirfenidone may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinPirfenidone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Pirfenidone.Approved
SpironolactonePirfenidone may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Pirfenidone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Pirfenidone is combined with SRT501.Investigational
StreptomycinPirfenidone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinPirfenidone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazinePirfenidone may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Pirfenidone.Approved
SulodexidePirfenidone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Pirfenidone.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pirfenidone.Approved, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pirfenidone.Approved, Investigational
TacrolimusPirfenidone may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Pirfenidone.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Pirfenidone.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Pirfenidone.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pirfenidone.Approved, Investigational
TemafloxacinPirfenidone may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Pirfenidone.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pirfenidone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Teriflunomide.Approved
TG4010The risk or severity of adverse effects can be increased when Pirfenidone is combined with TG4010.Investigational
TheophyllineThe serum concentration of Pirfenidone can be increased when it is combined with Theophylline.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pirfenidone.Approved
TiclopidineThe serum concentration of Pirfenidone can be increased when it is combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tiludronate.Approved, Vet Approved
TimololPirfenidone may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tixocortol.Approved
TobramycinPirfenidone may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabTocilizumab may increase the immunosuppressive activities of Pirfenidone.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pirfenidone.Approved
TorasemidePirfenidone may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pirfenidone.Approved
TranilastThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pirfenidone.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pirfenidone.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pirfenidone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Triamcinolone.Approved, Vet Approved
TriamterenePirfenidone may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pirfenidone.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Pirfenidone.Approved
TrovafloxacinPirfenidone may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Pirfenidone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinPirfenidone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Pirfenidone.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Pirfenidone.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Vedolizumab.Approved
WarfarinPirfenidone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPirfenidone may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Pirfenidone may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Pirfenidone.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pirfenidone.Withdrawn
ZorubicinPirfenidone may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Hale ML, Margolin SB, Krakauer T, Roy CJ, Stiles BG: Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun. 2002 Jun;70(6):2989-94. [PubMed:12010989 ]
  2. Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F: Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007 Oct;47(10):1268-76. [PubMed:17906160 ]
External Links
ATC CodesL04AX05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9932
Blood Brain Barrier+0.996
Caco-2 permeable+0.8614
P-glycoprotein substrateNon-substrate0.8193
P-glycoprotein inhibitor INon-inhibitor0.755
P-glycoprotein inhibitor IINon-inhibitor0.9177
Renal organic cation transporterNon-inhibitor0.8157
CYP450 2C9 substrateNon-substrate0.6638
CYP450 2D6 substrateNon-substrate0.8248
CYP450 3A4 substrateSubstrate0.6111
CYP450 1A2 substrateInhibitor0.9108
CYP450 2C9 inhibitorNon-inhibitor0.5982
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.7166
CYP450 3A4 inhibitorNon-inhibitor0.775
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7633
Ames testNon AMES toxic0.7652
CarcinogenicityNon-carcinogens0.8992
BiodegradationNot ready biodegradable0.9112
Rat acute toxicity2.1330 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9784
hERG inhibition (predictor II)Non-inhibitor0.6301
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral267 mg/1
CapsuleOral267 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7566729 No2009-04-222029-04-22Us
US7635707 No2009-04-222029-04-22Us
US7696236 No2007-12-182027-12-18Us
US7767225 No2006-09-222026-09-22Us
US7767700 No2007-12-182027-12-18Us
US7816383 No2010-01-082030-01-08Us
US7910610 No2010-01-082030-01-08Us
US7988994 No2006-09-222026-09-22Us
US8013002 No2010-01-082030-01-08Us
US8084475 No2010-01-082030-01-08Us
US8318780 No2010-01-082030-01-08Us
US8383150 No2006-09-222026-09-22Us
US8420674 No2007-12-182027-12-18Us
US8592462 No2009-04-222029-04-22Us
US8609701 No2009-04-222029-04-22Us
US8648098 No2010-01-082030-01-08Us
US8753679 No2006-09-222026-09-22Us
US8754109 No2010-01-082030-01-08Us
US8778947 No2013-08-302033-08-30Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility2.89 mg/mLALOGPS
logP2ALOGPS
logP2.14ChemAxon
logS-1.8ALOGPS
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity57 m3·mol-1ChemAxon
Polarizability20.28 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinones. These are compounds containing a pyridine ring, which bears a ketone.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentPyridinones
Alternative Parents
Substituents
  • Methylpyridine
  • Pyridinone
  • Dihydropyridine
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Lactam
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Furin is likely to represent the ubiquitous endoprotease activity within constitutive secretory pathways and capable of cleavage at the RX(K/R)R consensus motif.
Gene Name:
FURIN
Uniprot ID:
P09958
Molecular Weight:
86677.375 Da
References
  1. Burghardt I, Tritschler F, Opitz CA, Frank B, Weller M, Wick W: Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354(2):542-7. Epub 2007 Jan 10. [PubMed:17234158 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on December 05, 2016 02:44